Assyro AI

Purple Book product · Reference 351(a)

Genotropin

somatropin

351(a)BLA 020280RxLicensed Pharmacia & Upjohn Company LLC

At a glance

Jan 27, 1998

Approved

Reference 351(a)

License type

Rx

Marketing

No

Patents listed

Key dates

  1. Approval

    Approval date of this BLA submission.

    Jan 27, 1998

    28 yr 9 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Jul 25, 2008

    18 yr 1 mo ago

  3. Today

Pharmaceutical detail

Strength

1.2MG

Dosage form

For Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

1216

Product number

009

Submission type

Supplement

Supplement number

9

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Taxonomy and ontology

12 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(a)

blaType · 351(a)

application pathway

Section 351(a) Biologic

blaType · 351(a)

product role

Reference or Standalone Biologic

blaType · Reference product

marketing status

Prescription

marketingStatus · Rx

licensure status

Licensed

licensure · Licensed

route

Subcutaneous

routeOfAdministration · Subcutaneous

dosage form

For Injection

dosageForm · For Injection

source kind

Monthly Download

sourceKind · monthly_download

  • Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(a) Biologicmaps to351(a)
  • 351(a)classifiesReference or Standalone Biologic

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.